---
schema_version: "secwatch.filing_event.v1"
accession: "0000805928-23-000146"
form_type: "8-K"
ticker: "AXGN"
cik: "0000805928"
company_name: "Axogen, Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T18:21:08.746733+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Axogen Q3 revenue $41.3M (+12% YoY); maintains FY2023 guidance $154-159M

## Summary
- Revenue $41.3M (+12% YoY); scheduled non-trauma grew ~20%, emergent trauma mid-single digits.
- Net loss $4.1M ($0.10/sh); adjusted net income $0.7M ($0.01/sh); Adj. EBITDA $2.4M vs $0.4M.
- Gross margin 80.5% (down from 83.3%); FY2023 gross margin expected ~80%.
- Cash & investments $38.6M; new processing facility began tissue processing in Aug.
- Core Accounts 372 (+12% YoY); revenue from Core Accounts now ~65% of total.

## SEC filing metadata
- accession: 0000805928-23-000146
- form_type: 8-K
- ticker: AXGN
- cik: 0000805928
- company_name: Axogen, Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/805928/000080592823000146/0000805928-23-000146-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/805928/000080592823000146/axgn-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000805928-23-000146
- JSON: https://secwatch.observer/filing/0000805928-23-000146.json
- Plain text: https://secwatch.observer/filing/0000805928-23-000146.txt

## Key facts
- Earnings Releases
  Axogen, Inc. reported full year 2023 results: revenue $154 million to $159 million. Guidance reaffirmed.
  - Period: full year 2023
  - Revenue: $154 million to $159 million
  - Guidance: reaffirmed
  - Result: guidance update
  source text: Management is maintaining full-year 2023 revenue guidance in the range of $154 million to $159 million, which represents annual growth of 11% - 15%.
  evidence_url: https://www.sec.gov/Archives/edgar/data/805928/000080592823000146/0000805928-23-000146-index.htm
- Earnings Releases
  Axogen, Inc. reported third quarter ended September 30, 2023 results: net income Net loss of $4.1 million, EPS $0.10 per share.
  - Period: third quarter ended September 30, 2023
  - Net income: Net loss of $4.1 million
  - EPS: $0.10 per share
  - Result: reported results
  source text: Revenue was $41.3 million during the third quarter, an increase of approximately 12% over the third quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/805928/000080592823000146/0000805928-23-000146-index.htm
- Earnings Releases
  Axogen, Inc. reported third quarter ended September 30, 2023 results: net income Net loss of $4.1 million, EPS $0.10 per share.
  - Period: third quarter ended September 30, 2023
  - Net income: Net loss of $4.1 million
  - EPS: $0.10 per share
  - Result: reported results
  source text: Net loss of $4.1 million, or $0.10 per share, compared to net loss of $4.3 million, or $0.10 per share in the third quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/805928/000080592823000146/0000805928-23-000146-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.